G
Georg Becker
Researcher at Leipzig University
Publications - 31
Citations - 1092
Georg Becker is an academic researcher from Leipzig University. The author has contributed to research in topics: Nicotinic agonist & Frontotemporal lobar degeneration. The author has an hindex of 15, co-authored 31 publications receiving 971 citations.
Papers
More filters
Journal ArticleDOI
Reduced α4β2*–Nicotinic Acetylcholine Receptor Binding and Its Relationship to Mild Cognitive and Depressive Symptoms in Parkinson Disease
Philipp Meyer,Karl Strecker,Kai Kendziorra,Georg Becker,Swen Hesse,Dominique Woelpl,Anke Hensel,Marianne Patt,Dietlind Sorger,Florian Wegner,Donald Lobsien,Henryk Barthel,Peter Brust,Hermann Josef Gertz,Osama Sabri,Johannes Schwarz +15 more
TL;DR: There is a broad reduction of alpha4beta2*-nAChR availability in patients with PD without clinically manifest dementia or depression compared with healthy volunteers, and novel in vivo evidence for a role of the cholinergic neurotransmission in psychiatric comorbidity of PD is provided.
Journal ArticleDOI
Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies
Juergen Dukart,Karsten Mueller,Annette Horstmann,Barbara Vogt,Stefan Frisch,Henryk Barthel,Georg Becker,Harald E. Möller,Arno Villringer,Arno Villringer,Osama Sabri,Matthias L. Schroeter,Matthias L. Schroeter +12 more
TL;DR: While cerebellar normalization seems to be more sensitive for early diagnosis, cerebral global normalization might be superior for differential diagnostic purposes in dementia syndromes.
Journal ArticleDOI
Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography
Kai Kendziorra,Henrike Wolf,Henrike Wolf,Philipp Meyer,Henryk Barthel,Swen Hesse,Georg Becker,Julia Luthardt,Andreas Schildan,Marianne Patt,Dietlind Sorger,Anita Seese,Herman-Josef Gertz,Osama Sabri +13 more
TL;DR: 2-[18F]FA-85380 PET appears to be a sensitive and feasible tool for the detection of a reduction in α4β2* nAChRs which seems to be an early event in AD.
Journal ArticleDOI
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Henryk Barthel,Julia Luthardt,Georg Becker,Marianne Patt,Eva Hammerstein,Kristin Hartwig,Birk Eggers,Bernhard Sattler,Andreas Schildan,Swen Hesse,Philipp Meyer,Henrike Wolf,Henrike Wolf,Torsten Zimmermann,Joachim Reischl,Beate Rohde,Hermann-Josef Gertz,Cornelia Reininger,Osama Sabri +18 more
TL;DR: Results indicate florbetaben to be a safe and efficacious β-amyloid-targeted tracer with favourable brain kinetics, which appeared valuable as a surrogate marker of disease severity.
Journal ArticleDOI
PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains
Georg Becker,Masanori Ichise,Henryk Barthel,Julia Luthardt,Marianne Patt,Anita Seese,Marcus Schultze-Mosgau,Beate Rohde,Hermann-Josef Gertz,Cornelia Reininger,Osama Sabri +10 more
TL;DR: The results suggest that compartment kinetic model–based quantification of β-amyloid binding from 18F-florbetaben PET data is feasible and that all β-amide binding parameters including SUVR are excellent in discriminating between β-AMyloid–positive and –negative scans.